Obesity research has rapidly emerged as one of the most dynamic fields in modern healthcare. With GLP-1-based therapies capturing global attention and metabolic disease emerging as a defining challenge of modern medicine, few organizations are as strategically positioned and scientifically grounded as Evolution Research Group (ERG) to progress this important area of research and development. Established in 2013 by Lori Wright, who remains Chief Executive Officer, ERG began as a multidisciplinary research network committed to scientific excellence and operational precision. Since its founding, the company has driven research forward in psychiatry, neurology, analgesia, early-phase clinical pharmacology, metabolism, and endocrinology. Guided by Lori Wright’s vision, ERG was built to translate scientific insight into high-quality clinical execution while anticipating the evolving needs of the industry. Under Lori Wright’s leadership, ERG has steadily expanded both its scientific depth and operational reach. The strategic addition of endocrinologist Dr. Sherwin Schwartz, in 2018, followed by Chief Scientific Officer Clay Dehn, PhD(c), significantly bolstered the company’s foundation in metabolic and obesity research. As global attention shifted toward obesity, ERG was uniquely positioned- with the expertise, infrastructure, and foresight- to lead in this rapidly evolving therapeutic area. Andria Chastain, President of ERG, characterizes the company’s evolution as both proactive and strategic. “We recognized early on that metabolic research would be pivotal to the future of healthcare, she explains. Our goal has always been to build a scientific foundation that evolves with industry needs.” Responding to Industry Shifts with Scientific Rigor Under the scientific leadership of Clay Dehn, ERG plays an active role in shaping the national landscape metabolic and obesity research. As ERG’s representative to the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, Dehn serves on the Metabolic Disorders Steering Committee. Through these strategic collaborations, ERG continues to advance solutions to critical challenges in metabolic disorder drug development, with a particular focus on obesity.
Cell and Gene Therapy
Gene therapy stands at an inflection point. Despite remarkable advances, many clinical programs have faltered against one stubborn obstacle: the immune system. Each failed clinical trial carries a heavy cost, not only in resources and hope but in the direct risk it poses to patient safety. NxGEN Vector Solutions’ CpG-depletion technology has emerged as a new standard, cited in FDA advisories and peer-reviewed studies across the field. By shifting the paradigm from capsid-only engineering to genome optimization, NxGEN has redefined what is possible for the next generation of adeno-associated virus (AAV)–based gene therapies. Gene therapy aims to replace or supplement faulty or missing genes responsible for serious, often life-threatening disorders. AAV vectors act as delivery vehicles, transporting healthy DNA into target tissues so the body can produce the proteins it needs. But for decades, a single biological barrier has stood in the way: the innate immune system. The body can mistake therapeutic AAV vectors, which act as delivery vehicles carrying precious genetic cargo, for viral invaders, triggering the Toll-like receptor 9 (TLR9) pathway. This sets off inflammatory cascades that compromise patient safety, curtail gene expression, limit efficacy, and prevent repeat dosing. NxGEN’s breakthrough came by pinpointing and removing the precise genetic signal—unmethylated CpG motifs—that ignite this immune response. By redesigning the AAV genome to eliminate these motifs, NxGEN created a new class of CpG-depleted vectors that avoid immune recognition, maintain transgene expression, and deliver therapeutic benefit safely. This discovery redefined the principles of durability and safety in gene therapy. NxGEN Vector Solutions’ platform now directly addresses the three greatest challenges faced by developers today: overcoming immune activation to prevent inflammatory responses; sustaining long-term gene expression for lasting benefit; and reducing clinical risk to improve success rates. By enabling AAV vectors to “fly under the immune radar,” NxGEN Vector Solutions has ushered in a new era of durable, repeatable, and safe genetic medicines— fulfilling the promise that gene therapy has long pursued..
Clinical Trial
Neuromodulation in Clinical Practice
Hesham Abboud, MD, PhD, Director, Multiple Sclerosis and Neuroimmunology Program, University Hospitals
Clinical Trial Management
Factors to Consider for Successful Outsourcing in the Cell and Gene Therapy Space
Jay Newman, Executive Director, Global Head, Research and Development Quality, and Kitty Brady, Director, Contract Development and Manufacturing Operations, CSL Behring
Clinical Trial
Inpatient Interdisciplinary Care Model with Pharmacy: Revisiting the Traditional Roles of Clinical Team Members
Lisa Boothby, Director of Pharmacy Services, Ochsner Health
Clinical Trial
Reimagining Telehealth through Scalable Technology
Gerard Frunzi, Regional Director Telehealth and Virtual Care, CommonSpirit Health Mountain Region
Clinical Trial
Strengthening Nursing Teams through Trust and Presence
Valerie Seccia, Director of Nursing Services, Temple Health
IN MY OPINION
Clinical Trial
Into the Healthcare Spectrum and Beyond
Vincent W. Green, Corporate Chief Medical Officer, Pipeline Health System
LAST WORD
Clinical Trial
Safeguarding People Irrespective of Caste, Creed and Color
Mark Amey, Chief Information Officer, Alameda Health System
IN FOCUS
Beyond GLP-1s and the Next Wave of Anti-Obesity Modalities
A transformative shift in obesity treatment is underway, emphasizing GLP-1 receptor agonists and emerging multi-agonist therapies that redefine obesity as a treatable biological disease.
Reconciling Gene Therapy with Environmental Stewardship
Gene therapy has evolved into an industrialized field, focusing on scalable, sustainable manufacturing using advanced technologies, automation, and green practices to deliver innovative treatments globally.
EDITORIAL
Future-Ready Strategies for Complex Trials
Recent advances in data science, molecular analytics and digital study oversight are reshaping how these programs move from early discovery to late-stage validation. Developers can now monitor deeper biomarker activity and evolving safety signals with far greater accuracy, allowing them to refine decisions as trials progress.
A new wave of technologies is amplifying this progress by connecting scientific demands with more flexible operational execution. Adaptive data environments, continuous patient-tracking capabilities and integrated genomic interpretation are reinforcing both anti-obesity and gene therapy pipelines, bringing them closer to clinical readiness through more coordinated study management.
This edition of Life Sciences Review brings these developments into sharper view, linking scientific momentum with the operational strategies that enable therapies to advance with greater confidence.
Featured thought leaders include Lisa Boothby, director of pharmacy services at Ochsner Health, who underscores how pharmacists can help relieve nursing shortages by assuming inpatient medication administration and patient-focused education within an interdisciplinary care model. Jay Newman, executive director, global head, research and development quality, and Kitty Brady, director of contract development and manufacturing operations at CSL Behring, share insights on the strategic factors shaping CGT outsourcing. They stress that selecting a capable CDMO, backed by a well-governed and collaborative partnership, is essential for achieving consistent results.
The edition also features Evolution Research Group, a leading clinical research organization driving progress in metabolic and obesity drug development through scientific expertise and technology-enabled coordination across its research network.
We hope this edition offers a clear perspective on where the field is heading and supports your work as these therapeutic and operational models continue to evolve.
